TY - JOUR
T1 - Association between financial toxicity and health-related quality of life of patients with gynecologic cancer
AU - Kajimoto, Yusuke
AU - Honda, Kazunori
AU - Suzuki, Shiro
AU - Mori, Masahiko
AU - Tsubouchi, Hirofumi
AU - Nakao, Kohshiro
AU - Azuma, Anri
AU - Shibutani, Takashi
AU - Nagao, Shoji
AU - Koyanagi, Takahiro
AU - Kohara, Izumi
AU - Tamaki, Shuko
AU - Yabuki, Midori
AU - Teng, Lida
AU - Fujiwara, Keiichi
AU - Igarashi, Ataru
N1 - Publisher Copyright:
© 2023, The Author(s) under exclusive licence to Japan Society of Clinical Oncology.
PY - 2023
Y1 - 2023
N2 - Objectives: Patients often struggle with their financial situation during cancer treatment due to treatment-related costs or loss of income. This resulting negative effect is called financial toxicity, which is a known as a side effect of cancer care. This study aimed to evaluate the association between financial toxicity and health-related quality of life among patients with gynecologic cancer using validated questionnaires. Methods: In this multicenter study, patients with gynecologic cancer receiving anti-cancer drug treatment for > 2 months were recruited. Patients answered the COmprehensive Score for Financial Toxicity (COST) tool, EORTC-QLQ-C30, disease-specific tools (EORTC-QLQ-OV28/CX24/EN24), and EQ-5D-5L. Spearman’s rank correlation coefficient was used to determine associations. Results: Between April 2019 and July 2021, 109 cancer patients completed the COST questionnaire. The mean COST score was 19.82. Strong associations were observed between financial difficulty (r = − 0.616) in the EORTC-QLQ-C30 and body image (r = 0.738) in the EORTC-QLQ-CX24, while weak associations were noted between the global health status/quality of life (r = 0.207), EQ-5D-5L index score (r = 0.252), and several function and symptom scale scores with the COST score. Conclusions: Greater financial toxicity was associated with worse health-related quality of life scores, such as financial difficulty in gynecologic cancer patients and body image in cervical cancer patients as strong associations, and weakly associated with general health-related quality of life scores and several function/symptom scales.
AB - Objectives: Patients often struggle with their financial situation during cancer treatment due to treatment-related costs or loss of income. This resulting negative effect is called financial toxicity, which is a known as a side effect of cancer care. This study aimed to evaluate the association between financial toxicity and health-related quality of life among patients with gynecologic cancer using validated questionnaires. Methods: In this multicenter study, patients with gynecologic cancer receiving anti-cancer drug treatment for > 2 months were recruited. Patients answered the COmprehensive Score for Financial Toxicity (COST) tool, EORTC-QLQ-C30, disease-specific tools (EORTC-QLQ-OV28/CX24/EN24), and EQ-5D-5L. Spearman’s rank correlation coefficient was used to determine associations. Results: Between April 2019 and July 2021, 109 cancer patients completed the COST questionnaire. The mean COST score was 19.82. Strong associations were observed between financial difficulty (r = − 0.616) in the EORTC-QLQ-C30 and body image (r = 0.738) in the EORTC-QLQ-CX24, while weak associations were noted between the global health status/quality of life (r = 0.207), EQ-5D-5L index score (r = 0.252), and several function and symptom scale scores with the COST score. Conclusions: Greater financial toxicity was associated with worse health-related quality of life scores, such as financial difficulty in gynecologic cancer patients and body image in cervical cancer patients as strong associations, and weakly associated with general health-related quality of life scores and several function/symptom scales.
KW - Financial toxicity
KW - Gynecology
KW - Health care costs
KW - Patient-reported outcome measures
KW - Quality of life
UR - http://www.scopus.com/inward/record.url?scp=85146391464&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85146391464&partnerID=8YFLogxK
U2 - 10.1007/s10147-023-02294-1
DO - 10.1007/s10147-023-02294-1
M3 - Article
C2 - 36648710
AN - SCOPUS:85146391464
SN - 1341-9625
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
ER -